-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the rapid development of biotechnology, the domestic biopharmaceutical market has ushered in a trend.
In addition to the gradual rise of a large number of biopharmaceutical companies, which occupy an increasingly important position in the pharmaceutical field, the growth potential of the entire market is also increasing.
.
Forecasts show that the size of China's biopharmaceutical market in 2021 will exceed 317.
2 billion yuan in 2019, breaking the 400 billion yuan mark to 464.
4 billion yuan
.
The proportion of biopharmaceutical equipment in pharmaceutical machinery companies is accelerating! (Image source: Pharmaceutical Network) The industry believes that under this background, in addition to the rapid growth of biological products and vaccines in the biomedical field, the prospects are impressive; the CXO industry in the innovative drug industry chain also continues to maintain a high growth trend
.
It is worth mentioning that this will also bring more new opportunities to the upstream pharmaceutical equipment industry, and orders from related companies will continue to grow
.
According to the author's understanding, since 2021, the proportion of domestic pharmaceutical equipment companies and biopharmaceutical equipment has been accelerating, and their performance has continued to improve
.
For example, after being investigated by 25 institutions, Chutian issued an announcement on November 29 that the layout of bio front-end equipment against Sartorius was gradually improved, including stainless steel reactors, stock solution preparation, ultrafiltration chromatography purification, and SUT disposable technology.
The deployment of products, fillers, etc.
is one of the highlights of this year's business
.
Prior to this, he also mentioned that the growth of biopharmaceuticals will drive the company's business growth, and the company's bioengineering sector will account for an increasing proportion in the future
.
Xinlai Yingcai also mentioned in the intensive survey conducted by a large number of institutions such as Debon Fund, Haitong Asset Management, and China Sea Securities on November 1 that the company's overall business progressed well in the first three quarters of 2021, and the food sector business maintained steady growth.
The business of the biomedical sector benefited from the rapid growth of domestic and foreign vaccine companies' production expansion
.
In addition, Tofflon mentioned the changes in the company's revenue structure in the survey activity information table at the end of October.
It also stated that the increase in the proportion of bioengineering and cell equipment was one of the reasons for the company's 46% gross profit margin in the first three quarters
.
From the above comprehensive point of view, the analysis believes that the proportion of biopharmaceutical equipment of the pharmaceutical giants has increased rapidly, which is closely related to the high prosperity of the biomedical industry
.
With the rapid development of the biopharmaceutical industry, the industry predicts that the upstream including biopharmaceutical equipment will usher in greater development space in 2022, and the performance of related companies in biological equipment will continue to grow
.
But what needs to be noticed is that although domestic back-end equipment including filling lines and post-packaging lines can basically meet the needs of biopharmaceutical companies, it is used in high-end biopharmaceutical equipment, such as some relatively technically difficult front-end equipment.
, The domestic market is still dominated by foreign pharmaceutical giants, so it will be the next stage of the goal of domestic enterprises to develop high-end equipment
.
It is worth mentioning that under this background, domestic biopharmaceutical equipment companies such as Tofflon, Chutian Technology, etc.
may be expected to further accelerate the pace of import substitution and achieve new growth
.
In general, the rapid development of biopharmaceutical technology, the market development potential will also continue to increase
.
It is predicted that the size of China's biopharmaceutical market will rapidly expand at an average compound annual growth rate of 18% in the next few years, and reach 59 billion yuan in 2030
.
Under the influence of the ever-expanding market, pharmaceutical machinery companies need to seize the opportunity to accelerate the promotion of the pharmaceutical equipment industry into a new round of upgrading and upgrading by introducing AI technology, and continue to meet the needs of pharmaceutical companies for advanced, higher-end, more efficient, and Demand for more environmentally friendly pharmaceutical equipment
.
In addition to the gradual rise of a large number of biopharmaceutical companies, which occupy an increasingly important position in the pharmaceutical field, the growth potential of the entire market is also increasing.
.
Forecasts show that the size of China's biopharmaceutical market in 2021 will exceed 317.
2 billion yuan in 2019, breaking the 400 billion yuan mark to 464.
4 billion yuan
.
The proportion of biopharmaceutical equipment in pharmaceutical machinery companies is accelerating! (Image source: Pharmaceutical Network) The industry believes that under this background, in addition to the rapid growth of biological products and vaccines in the biomedical field, the prospects are impressive; the CXO industry in the innovative drug industry chain also continues to maintain a high growth trend
.
It is worth mentioning that this will also bring more new opportunities to the upstream pharmaceutical equipment industry, and orders from related companies will continue to grow
.
According to the author's understanding, since 2021, the proportion of domestic pharmaceutical equipment companies and biopharmaceutical equipment has been accelerating, and their performance has continued to improve
.
For example, after being investigated by 25 institutions, Chutian issued an announcement on November 29 that the layout of bio front-end equipment against Sartorius was gradually improved, including stainless steel reactors, stock solution preparation, ultrafiltration chromatography purification, and SUT disposable technology.
The deployment of products, fillers, etc.
is one of the highlights of this year's business
.
Prior to this, he also mentioned that the growth of biopharmaceuticals will drive the company's business growth, and the company's bioengineering sector will account for an increasing proportion in the future
.
Xinlai Yingcai also mentioned in the intensive survey conducted by a large number of institutions such as Debon Fund, Haitong Asset Management, and China Sea Securities on November 1 that the company's overall business progressed well in the first three quarters of 2021, and the food sector business maintained steady growth.
The business of the biomedical sector benefited from the rapid growth of domestic and foreign vaccine companies' production expansion
.
In addition, Tofflon mentioned the changes in the company's revenue structure in the survey activity information table at the end of October.
It also stated that the increase in the proportion of bioengineering and cell equipment was one of the reasons for the company's 46% gross profit margin in the first three quarters
.
From the above comprehensive point of view, the analysis believes that the proportion of biopharmaceutical equipment of the pharmaceutical giants has increased rapidly, which is closely related to the high prosperity of the biomedical industry
.
With the rapid development of the biopharmaceutical industry, the industry predicts that the upstream including biopharmaceutical equipment will usher in greater development space in 2022, and the performance of related companies in biological equipment will continue to grow
.
But what needs to be noticed is that although domestic back-end equipment including filling lines and post-packaging lines can basically meet the needs of biopharmaceutical companies, it is used in high-end biopharmaceutical equipment, such as some relatively technically difficult front-end equipment.
, The domestic market is still dominated by foreign pharmaceutical giants, so it will be the next stage of the goal of domestic enterprises to develop high-end equipment
.
It is worth mentioning that under this background, domestic biopharmaceutical equipment companies such as Tofflon, Chutian Technology, etc.
may be expected to further accelerate the pace of import substitution and achieve new growth
.
In general, the rapid development of biopharmaceutical technology, the market development potential will also continue to increase
.
It is predicted that the size of China's biopharmaceutical market will rapidly expand at an average compound annual growth rate of 18% in the next few years, and reach 59 billion yuan in 2030
.
Under the influence of the ever-expanding market, pharmaceutical machinery companies need to seize the opportunity to accelerate the promotion of the pharmaceutical equipment industry into a new round of upgrading and upgrading by introducing AI technology, and continue to meet the needs of pharmaceutical companies for advanced, higher-end, more efficient, and Demand for more environmentally friendly pharmaceutical equipment
.
